Faculty Publications

Clinical activity of the immunoconjugate CMC-544 in B-Cell malignancies: Preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase 1 study

Fayad L, Patel H, Verhoef G, Czuczman M, Foran J, Gine E, Rohatiner A, Smith MR, Shapiro M, Advani A

Clinical activity of the immunoconjugate CMC-544 in B-Cell malignancies: Preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase 1 study

Blood. 2006 Nov;108(11):766A-766A.

Abstract

Last updated on Saturday, November 21, 2009